An interventional study of WB-EMS and Control in Hypertension, Metabolic Syndrome and Hypercholesterolemia, sponsored by University of Erlangen-Nürnberg Medical School. Active, not recruiting at 2 sites in Germany. Open to male participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School — 2 open to participants now, 3 under way, none of them phase 3. Hypertension · University of Erlangen-Nürnberg Medical School.
Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 14th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →2 of the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School are open now, in 1 country. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75 · Healthy volunteers
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–99
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 50 Years to 70 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 4 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 28 across the 11 interventional studies, 27 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.
3 of the studies in Hypertension by University of Erlangen-Nürnberg Medical School that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07359664University of Erlangen-Nürnberg Medical SchoolOCTA in Cardiovascular Disease and Healthy Controls | 2026-12 |
| NCT06556407University of Erlangen-Nürnberg Medical SchoolEffect of Renal Denervation on Bood Pressure in Patients on Hemodialysis | 2026-12-01 |
| NCT07406191University of Erlangen-Nürnberg Medical SchoolWB-EMS Effects on Cardiometabolic Risk Factors | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
From the age of 50 onwards, there is a disproportionate decline in muscle strength, mass and function, which can be prevented or at least delayed by physical training. Unfortunately, many training programmes are very time-consuming and strenuous and are therefore not carried out consistently. Whole-body electromyostimulation (WB-EMS), a technology in which all major muscle groups are stimulated with an adjusted stimulation level, could be a time-effective and joint-friendly alternative.
However, there are some contraindications to the widespread use of this technology, which are particularly common in middle-aged and elderly people. For example, high blood pressure, which affects more than half of men over the age of 50 in Germany, is considered a contraindication for WB-EMS training. However, this assessment is not very reliable; at least, acute WB-EMS application does not lead to an increase in blood pressure. In addition, there are no study results available for long-term WB-EMS application in people with high blood pressure.
The present study particularly investigate whether and to what extent several weeks of WB-EMS training has an effect on resting blood pressure in people with mild blood pressure. Additionally, the effect of WB-EMS on other cardiometabolic risk factors and physical function will be addressed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 weeks of Whole-body electromyostimulation, 1.5x 20min/week
Other: WB-EMS
12 weeks without additional intervention.
Other: Control
12 weeks of WB-EMS, 1.5x20 min/week
Also known as: Electromyostimulation
12 weeks without additional intervention and without life style changes
Also known as: Non-intervention control group
Resting blood pressure
Changes of mean arterial blood pressure after 10 min of rest in a sitting position as assessed by an automatic sphygmomanometer
Time frame: At baseline and after 12 weeks of intervention
Metabolic syndrome
Changes of the Metabolic Syndrome (MetS) as determined by the MetS-Z-Score
Time frame: At baseline and after 12 weeks of intervention
Body fat rate
Changes of body fat rate as determined by Bio Impedance Analysis (BIA)
Time frame: At baseline and after 12 weeks of intervention
Lean body mass
Changes of lean body mass as determined by Bio Impedance Analysis (BIA)
Time frame: At baseline and after 12 weeks of intervention
Maximum muscle strength
Changes of maximum hip-/leg extension strength as determined by a leg press
Time frame: At baseline and after 12weeks of intervention
Aerobic capacity
Changes of aerobic capacity as determined by a stepwise crosstrainer test to submaximum exertion
Time frame: At baseline and after 12 weeks of intervention
Lower extremity muscle power
Changes of lower extremity muscle power as determined by a 5times sit to stand test
Time frame: At baseline and after 12 weeks of intervention
Concentration of inflammatory markers
Changes of inflammatory markers as determined by cytokines
Time frame: At baseline and after 12 weeks of intervention
Concentration of adipose-tissue derived hormones
Changes of adipose tissue-derived hormones as determined by adipokines
Time frame: At baseline and after 12 weeks of intervention
Concentration of muscle-tissue derived hormones
Changes of muscle-tissue derived hormones as determined by myokines
Time frame: At baseline and after 12 weeks of intervention
Bluthochdruck - Fragebogen zur Lebenszufriedenheit [Hypertension - Quality of Life Questionnaire]
Changes in QoL in people with hypertension according to a questionnaire from 1 (excellent, completely agree) to 6 (very bad/completely disagree). Lower scores indicate better outcomes
Time frame: At baseline and after 12 weeks of intervention
Sleep Quality Index (PSQI)
Changes in sleep quality according to the Pittsburgh Sleep Quality Index questionnaire on a scale from 1 (worst outcome) to 4 (best outcome). Higher scores indicate better sleep quality.
Time frame: At baseline and after 12 weeks of intervention
Adverse effects
All categories of adverse effects as determined by structured monthly telephone interview
Time frame: From baseline assessment to 12 week control assessment (during the intervention)
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 21 months is close to that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Erlangen-Nürnberg Medical School →